Who Should Not Take a GLP-1: Contraindications, Cautions and the Boxed Warning
Approved GLP-1 labelling carries a boxed warning on thyroid C-cell tumours based on rodent studies, and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pregnancy, pancreatitis history, severe gastrointestinal disease and existing diabetic retinopathy all require specific assessment.
What the labelling states
| Category | Situation | Status |
|---|---|---|
| Contraindicated | Personal or family history of medullary thyroid carcinoma | Boxed warning |
| Contraindicated | Multiple Endocrine Neoplasia syndrome type 2 | Boxed warning |
| Contraindicated | Known hypersensitivity to the product | Absolute |
| Not recommended | Pregnancy | Discontinue in advance of a planned pregnancy |
| Caution | History of pancreatitis | Prescriber assessment |
| Caution | Existing diabetic retinopathy | Rapid glycaemic change is relevant |
| Caution | Severe gastroparesis or GI disease | Mechanism compounds the condition |
| Caution | On insulin or a sulfonylurea | Hypoglycaemia risk; regimen review |
| Caution | History of gallbladder disease | Rapid weight loss is a risk factor |
A summary of labelled considerations, not a complete safety profile. Read the medication guide and speak to a prescriber.
The pregnancy timing question
Labelling advises discontinuing in advance of a planned pregnancy, with the interval reflecting how long the drug persists. There is a second point people miss: weight loss can restore ovulation in people who were not ovulating, and oral contraceptive absorption can be affected by delayed gastric emptying. Both make unplanned pregnancy more likely at exactly the point the drug is not recommended.
What is not a contraindication
- Age alone. Older adults were included in trials; frailty and lean mass are separate considerations.
- A previous failed attempt at weight loss. That is the trial population.
- Not having diabetes. The weight-management approvals are in people without it.
1 = should be asked before a first prescription. Count how many your intake covered.
What compounded programmes change about screening
The contraindications belong to the molecule, not the label. A compounded semaglutide preparation carries the same thyroid contraindication as branded semaglutide, because it is the same active ingredient — assuming it is the base form, which is a separate question worth asking.
What can differ is the rigour of the screening. An approved product is dispensed against a prescription written after an assessment. A compounded product from a telehealth platform is dispensed against a prescription written after whatever that platform's intake asked, and intakes vary enormously.
| Should ask | A thin intake asks |
|---|---|
| Thyroid and MEN 2 history | Height and weight |
| Pregnancy status and plans | Goal weight |
| Pancreatitis history | Whether you have tried dieting |
| Full current medicines list | — |
| Retinopathy status | — |
| Gastrointestinal disease | — |
The left column is what the labelled contraindications require. Count how many you were asked.
Common questions
How serious is the thyroid warning?
It is a boxed warning, the strongest category, based on rodent studies. Whether it translates to humans is not established — which is precisely why the labelling contraindicates the specific histories rather than warning everyone. If you have a personal or family history of medullary thyroid carcinoma or MEN 2, it applies to you directly.
What if I have a family history I do not know about?
Worth asking relatives before starting, particularly about thyroid cancer. It is the one item on the list that requires information you may not have.
Can I take a GLP-1 with other medicines?
Usually, with review. Insulin and sulfonylureas raise hypoglycaemia risk and often need adjustment, and delayed gastric emptying can affect absorption of oral medicines including contraceptives. Bring a full list.
My intake did not ask about any of this. Is that a problem?
It tells you how the programme is run. The screening exists because the labelling requires it, and a platform that skips it is not applying the standard the approved product is dispensed under.
The interactions worth naming
| What | Why | What usually happens |
|---|---|---|
| Insulin | Hypoglycaemia risk rises | Dose review, often reduction |
| Sulfonylureas | Same | Dose review |
| Oral contraceptives | Delayed gastric emptying affects absorption | Discuss backup contraception |
| Narrow-therapeutic-index oral drugs | Absorption timing shifts | Monitoring |
| Warfarin | Absorption and diet changes | INR monitoring |
| Existing retinopathy | Rapid glycaemic change is relevant | Ophthalmology input |
This is why a full current-medicines list belongs in any intake, and why a three-question quiz cannot substitute for one.
What "not recommended in pregnancy" means in practice
Three things at once, and they interact badly:
- The labelling advises discontinuing in advance of a planned pregnancy, with the interval reflecting how long the drug persists.
- Weight loss can restore ovulation in people who were not ovulating — so fertility can return unexpectedly during treatment.
- Oral contraceptive absorption can be affected by delayed gastric emptying, particularly around dose increases.
The combination makes unplanned pregnancy more likely at exactly the point the drug is not recommended. Anyone who could become pregnant should have this conversation before starting rather than after.
Common questions
What if I have a history of pancreatitis?
It is a caution rather than an absolute contraindication, and it is a prescriber's assessment against your specific history. It belongs on any intake form.
Are the contraindications different for compounded products?
No. They belong to the molecule. What differs is how thoroughly a given programme screens for them.
Can I take a GLP-1 with a thyroid condition?
The contraindication is specific: medullary thyroid carcinoma or MEN 2, personal or family history. Other thyroid conditions, including hypothyroidism, are not the same question — but tell the prescriber what you have.
Out of six labelled screening areas: thyroid and MEN 2, pregnancy, pancreatitis, current medicines, retinopathy and gastrointestinal disease. Count what yours asked.
What this page does not settle
- Whether a GLP-1 is right for you. That is a prescriber's assessment against your full history.
- How the boxed warning translates from rodents to humans. Not established, which is why the contraindication is specific rather than universal.
- Every interaction. Bring a complete medicines list; this page names the common ones.
The most actionable line here is the simplest: if your intake did not ask about thyroid history, it did not screen for the contraindication carrying the boxed warning. That is worth knowing about any programme before the first injection.